Genetically Determined Fructose Intolerance: Symptoms, Diagnosis, and Dietary Recommendations

Hereditary fructose intolerance, alternatively termed fructosemia, constitutes a genetic metabolic disorder defined by the absence or severe deficiency of aldolase B (fructose-1-phosphate aldolase), an enzyme essential for the proper catabolism of fructose within cellular pathways. The condition follows an autosomal recessive inheritance pattern—meaning the causative genetic mutation, located on chromosome 9 (and thus unrelated to sex), must be inherited from both parents for phenotypic expression. Classified among rare diseases, its estimated prevalence ranges from 1 to 9 cases per 100,000 individuals. The underlying pathophysiology stems from the intracellular accumulation of fructose-1-phosphate, a toxic intermediate that disrupts multiple metabolic processes: it elevates uric acid levels, depletes magnesium stores, impairs protein biosynthesis, and induces cellular injury. Given that aldolase B is predominantly expressed in intestinal epithelial cells, renal tubules, and hepatocytes, the liver, kidneys, and small intestine emerge as the primary organs vulnerable to progressive damage.

One of the most distinctive features of this condition is an innate aversion to fructose-rich foods—affected individuals consistently avoid consuming fruits in various forms, including juices, purées, or vegetable-based dishes, as well as certain confectionery products containing this simple sugar. Additional clinical symptoms typically emerge during infancy, coinciding with the dietary expansion phase when new components such as vegetable soups, fruit juices, or purées are introduced. There have also been documented instances where symptoms manifested earlier in infants fed modified milk formulas containing sucrose (a disaccharide composed of glucose and fructose), as reported in a 2018 study by H. Li et al. However, in Poland, the addition of sucrose to such formulas is not a standard practice. Following the consumption of fructose-containing meals, patients may experience nausea, vomiting, abdominal pain, generalized lethargy, excessive drowsiness, and, in severe cases, convulsions. Prolonged intake of high-fructose foods can lead to progressive liver damage, evidenced by hepatomegaly, as well as renal failure, confirmed by the presence of fructose molecules in the urine. Another significant symptom is hypoglycemia—reduced blood glucose levels, particularly postprandial—which stems from impairments in gluconeogenesis, the process of glucose synthesis from non-carbohydrate substrates. In certain cases, hypoglycemia may become severe and pose an immediate threat to life. Elevated uric acid levels may additionally precipitate gout-like symptoms. Furthermore, younger patients frequently exhibit delayed growth relative to their peers.

The clinical presentation of hereditary fructose intolerance may result in symptoms of varying intensity, many of which lack specificity and are also observed in other medical conditions. Consequently, the disorder often remains unrecognized for extended periods. Potential indicators of its presence may include abnormalities detected in urinalysis, such as the identification of fructose, alongside alterations in blood chemistry: diminished levels of glucose and phosphate, coupled with elevated concentrations of magnesium, uric acid, and lactic acid, which may culminate in lactic acidosis. However, these findings do not constitute definitive diagnostic criteria. Given the hereditary nature of the condition, a thorough familial medical history is essential, particularly regarding prior diagnoses of fructose intolerance or unexplained hepatic or renal dysfunction among relatives. While such historical data may suggest an increased likelihood of the disorder, they do not confirm its presence, just as their absence does not preclude the possibility of the condition. In certain instances, a fructose tolerance test may be administered, though it carries the risk of inducing severe hypoglycemia in the patient. For this reason, genetic testing is recommended as the gold standard for confirming the diagnosis by identifying the mutation responsible for the disease. The management of hereditary fructose intolerance primarily involves acute interventions aimed at treating organ-related complications—such as liver or kidney impairment—as well as addressing acute symptoms, including hypoglycemia. Over the long term, the cornerstone of therapy is the implementation of a tailored elimination diet designed to prevent symptom recurrence.

The fundamental objective of this dietary framework is the complete exclusion of fructose and other commonly used sweeteners—particularly sorbitol and sucrose—from daily nutritional intake. Currently, there are no definitive, evidence-based guidelines establishing a safe threshold for fructose consumption among patients, a circumstance attributable in part to individual variations in tolerance to this sugar, which is primarily contingent upon the body’s residual enzymatic activity. A further complicating factor is the challenge of accurately determining the precise fructose content in food products and monitoring its actual dietary intake. Consequently, the optimal approach involves striving for the maximal reduction of this carbohydrate in the nutritional plan, with heightened emphasis during the first two years of a child’s life, when metabolic systems are most vulnerable to dysregulation.

Individuals diagnosed with hereditary fructose intolerance (HFI) must rigorously exclude all dietary sources of fructose, including free fructose, sucrose (table sugar), polyols such as sorbitol, xylitol, maltitol, and erythritol, as well as prebiotic fibers like inulin. Consequently, the consumption of most fruits—with the sole exceptions of avocado and minimal quantities of rhubarb—is strictly prohibited, along with fruit preserves (jams, marmalades, fruit butters), granulated sugar, honey, and any products containing these ingredients. Meticulous scrutiny of ingredient labels is imperative, particularly for processed and ready-to-eat foods (e.g., deli meats, melted cheeses, condiments such as ketchup, mustard, mayonnaise, and salad dressings), spice blends, and pharmaceuticals in syrup, coated-tablet, or drop formulations—many of which incorporate sucrose or sorbitol as excipients. Similar diligence must be exercised when selecting dietary supplements and oral hygiene products (e.g., toothpaste), as these frequently contain restricted components. Safe alternatives include pure glucose (or glucose-based preparations), lactose (milk sugar), and synthetic sweeteners such as saccharin and aspartame—though the latter must not be exposed to heat due to potential degradation. Culinary techniques significantly influence fructose content: cooking vegetables reduces their fructose levels, making thermally processed vegetables preferable to raw ones. Likewise, technological processes such as grain refining diminish fructose concentrations, justifying the preference for white bread over whole-grain varieties. Given the diet’s restrictive nature, patients are at heightened risk of deficiencies in water-soluble vitamins—particularly folic acid (vitamin B9) and vitamin C (ascorbic acid). Targeted supplementation with fructose-free formulations of these nutrients is therefore essential. Additionally, inadequate fiber intake may precipitate constipation, necessitating the introduction of safe, fiber-based supplements. The elimination diet must be adhered to lifelong, with the most stringent restrictions applying during early childhood (particularly before age 2), which may be modestly relaxed in later years. While strict dietary compliance substantially reduces the likelihood of hepatic and renal complications, it does not entirely preclude their occurrence. For this reason, patients require ongoing medical supervision, with individualized schedules for follow-up visits and diagnostic evaluations to monitor growth, organ function, and overall health status.